RVNC - Revance Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Revance Therapeutics, Inc.

7555 Gateway Boulevard
Newark, CA 94560
United States
510-742-3400
http://www.revance.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees136

Key Executives

NameTitlePayExercisedYear Born
Mr. L. Daniel BrowneCo-Founder, CEO, Pres & Director783.49kN/A1962
Dr. Abhay JoshiChief Operating Officer800.88kN/A1963
Mr. Todd Erik ZavodnickChief Commercial Officer and Pres of Aesthetics & TherapeuticsN/AN/A1972
Ms. Lauren P. SilvernailCFO, Chief Bus. Officer & Sec.651.86kN/A1959
Ms. Jeanie D. HerbertSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Corporate Governance

Revance Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2018 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.